← Back to Volume 7

Comparative Analysis of ICIs, CAR-T Therapy, and Cancer Vaccines in Immunotherapy

Junyi Chen, Ansong Liu, Yao Yao
pp.402-408 DOI: 10.62051/6ef5pk41 December 24, 2024
Download PDF
Abstract: Immunotherapy is a popular cancer treatment, which mainly focuses on regulating the body's own immune response to achieve the goal of treatment. There are many different treatments available in this field, each with its own advantages and disadvantages. But there are still problems that have not yet been resolved. This article analyzes the research of ICIs, CAR-T cell therapy, and tumor vaccines, summarizes their characteristics and compares them. This study provides a horizontal comparison of ICIs, CAR-T therapies, and cancer vaccines in terms of efficacy, safety, and adaptability in cancer treatment. ICIs demonstrate broad applicability and validated efficacy but are not universally effective. CAR-T therapies show significant efficacy in hematological malignancies but face challenges in solid tumors. Cancer vaccines offer potential but are less universally effective. Safety profiles vary, with ICIs manageable through pharmacological interventions, CAR-T therapies requiring careful management due to serious side effects, and cancer vaccines showing generally mild adverse events. However, there are still substantive problems that have not been solved, and future research can focus on clinical research directions.
Keywords: Immune checkpoint inhibitors; CAR-T cell therapy; tumor vaccines；immunotherapy and its mechanisms.
APA Citation: Junyi Chen, Ansong Liu, Yao Yao (2024). Comparative Analysis of ICIs, CAR-T Therapy, and Cancer Vaccines in Immunotherapy. Transactions on Materials, Biotechnology and Life Sciences, 7(1), 402-408. https://doi.org/10.62051/6ef5pk41

References

  1. Vishweshwaraiah, Yashavantha L, and Nikolay V Dokholyan. mRNA vaccines for cancer immunotherapy. Frontiers in immunology, 2022, 13:1029069.
  2. Awad, Mark M, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer cell, 2022, 40(9):1010-1026.e11.
  3. Jung, Minkyu, et al. First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer. Cancer research and treatment, 2024, 56(1):208-218.
  4. Vincent, Benjamin G, et al. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. Journal of immunology, 2023, 211(2):219-228.
  5. Igarashi, Yuka, and Tetsuro Sasada. Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. Journal of immunology research, 2020, 2020:5825401.
  6. Lin, Yang, et al. An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer. Vaccines, 2024, 12(7):727.
  7. Kantoff, Philip W, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine, 2010, 363(5):411-422.
  8. Sartor, Oliver, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England journal of medicine, 2021, 385(12):1091-1103.